Is fidaxomicin effective as a treatment for the North American Pulsed Field type 1 (NAP1) strains of Clostridium difficile (C diff)?

Updated: Jul 25, 2019
  • Author: Faten N Aberra, MD, MSCE; Chief Editor: BS Anand, MD  more...
  • Print

A study by Louie et al compared vancomycin (125 mg PO QID) with fidaxomicin (200 mg PO BID). [71] The study showed that fidaxomicin therapy had a similar efficacy and resulted in a significantly lower rate of recurrence of CDI not associated with the epidemic North American Pulsed Field type 1 strains. Fidaxomicin was approved by the FDA in May 2011.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!